Sign in →

Epic Test Code LAB160 Mumps Virus Antibody, IgG, Serum

Additional Codes

MML Code: MPPG

LIS Code: MVSA

NY State Approved

Yes

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Reporting Name

Mumps Ab, IgG, S

Method Name

Multiplex Flow Immunoassay (MFI)

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  14 days


Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Type

Serum

Specimen Minimum Volume

0.4 mL

Reference Values

Vaccinated: Positive (≥1.1 AI)

Unvaccinated: Negative (≤0.8 AI)

Reference values apply to all ages.

Report Available

Same day/1 to 3 days

Day(s) Performed

Monday through Saturday

CPT Code Information

86735

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject
Heat-inactivated specimen Reject

Useful For

Determination of postimmunization immune response of individuals to the mumps vaccine

 

Documentation of previous infection with mumps virus in an individual with no previous record of immunization to mumps virus

Clinical Information

The mumps virus is a member of the Paramyxoviridae family of viruses, which include parainfluenza virus serotypes 1-4, measles, respiratory syncytial virus, and metapneumovirus. Mumps is highly infectious among unvaccinated individuals and is typically transmitted through inhalation of infected respiratory droplets or secretions. Following an approximately 2-week incubation period, symptom onset is typically acute with a prodrome of low-grade fever, headache, and malaise.(1,2) Painful enlargement of the salivary glands, the hallmark of mumps, occurs in approximately 60% to 70% of infections and in 95% of patients with symptoms. Testicular pain (orchitis) occurs in approximately 15% to 30% of postpubertal men and abdominal pain (oophoritis) is found in 5% of postpubertal women.(1) Other complications include mumps-associated pancreatitis (<5% of cases) and central nervous system disease (meningitis <10% and encephalitis <1%).

 

Widespread routine immunization of infants with attenuated mumps virus has dramatically decreased the number of reported mumps cases in the United States. However, outbreaks continue to occur, indicating persistence of the virus in the general population.

 

Laboratory diagnosis of mumps is typically accomplished by detection of IgM- and IgG-class antibodies to the mumps virus. However, due to the widespread mumps vaccination program, in clinically suspected cases of acute mumps infection, serologic testing should be supplemented with virus isolation in culture or detection of viral nucleic acid by polymerase chain reaction testing in throat, saliva, or urine specimens.

Interpretation

Positive:

The presence of detectable IgG-class antibodies indicates prior exposure to the mumps virus through infection or immunization. Individuals testing positive are considered immune to the mumps virus.

 

Equivocal:

Submit an additional specimen for testing in 10 to 14 days to demonstrate IgG seroconversion if recently vaccinated or if otherwise clinically indicated.

 

Negative:

The absence of detectable IgG-class antibodies suggests no prior exposure to the mumps virus or the lack of a specific immune response to immunization.

Cautions

Mumps virus shares antigenic relationships with other viruses of the paramyxovirus group; therefore, serologic cross-reactions are possible, but uncommon with this test procedure.(2)

 

Immunoglobulin G-class antibodies to mumps virus may be present in serum specimens from individuals who have received blood products within the past several months but have not been immunized or experienced past infection with this virus.

 

Serum samples drawn early during acute phase of infection may be negative for IgG-class antibodies to this virus.

Supportive Data

To evaluate the accuracy of the BioPlex mumps IgG multiplex flow immunoassay (MFI), 500 prospective serum samples were analyzed in a blinded fashion by the SeraQuest mumps IgG enzyme immunoassay (EIA) and the BioPlex mumps IgG assay. Samples with discordant results after initial testing were repeated by both assays during the same freeze/thaw cycle. Further discrepancies were evaluated by the mumps IgG VIDAS enzyme-linked fluorescent immunoassay (ELFA; bioMerieux, Inc). The results are summarized below:

 

Table.

 BioPlex Mumps IgG

SeraQuest Mumps IgG EIA

Positive

Negative

Equivocal

Positive

412

4(a)

8

Negative

3(b)

48

3

Equivocal

5

6

11

 

(a) All 4 samples tested positive by VIDAS Mumps IgG ELFA

(b) One of 3 samples tested negative by the VIDAS Mumps IgG ELFA

Sensitivity: 98.1% (412/420); 95% CI: 96.2% to 99.1%

Specificity: 82.8% (48/58); 95% CI: 70.9% to 90.6%

Overall Percent Agreement: 94.2% (471/500); 95% CI: 91.8% to 96.0%

Specimen Retention Time

14 days